The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma

Histopathology

Volumn 63, Issue 6, 2013, Pages 852-861

  Avram, Gabriela ^a,b   Sánchez Sendra, Beatriz ^c   Martín, José M ^c   Terrádez, Liria ^d   Ramos, David ^a   Monteagudo, Carlos ^a,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d Hospital Manises   (Spain)

Author keywords

CC chemokine ligand 19; CC chemokine ligand 21; Chemokine CC receptor 7; Chemokines; High endothelial venules; MECA 79; Melanoma; Regression; Tumour infiltrating lymphocyte

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CYTOKINE ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MECA 79 ANTIBODY; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CUTANEOUS MELANOMA; DENSITY; DISTANT METASTASIS; FEMALE; HIGH ENDOTHELIAL VENULE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN-TRANSIT METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; METASTATIC MELANOMA; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR REGRESSION; VASCULAR ENDOTHELIUM; VENULE;

CC-CHEMOKINE LIGAND 19; CC-CHEMOKINE LIGAND 21; CHEMOKINE CC-RECEPTOR 7; CHEMOKINES; HIGH ENDOTHELIAL VENULES; MECA-79; MELANOMA; REGRESSION; TUMOUR-INFILTRATING LYMPHOCYTE;

ANTIGENS, SURFACE; CHEMOKINE CCL19; CHEMOKINE CCL21; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC VESSELS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; RECEPTORS, CCR7; RETROSPECTIVE STUDIES; RNA, MESSENGER; RNA, NEOPLASM; SKIN NEOPLASMS;

EID: 84887827961     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12235     Document Type: Article

References (31)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 2004; 150; 179-185.
2. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann. Oncol. 2009; 20(Suppl. 6); vi1-vi7.
3. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411; 375-379.
4. Förster R, Ohl L, Henning G. Lessons learned from lymphocytes: CC chemokine receptor-7 involved in lymphogenic metastasis of melanoma. J. Natl Cancer Inst. 2001; 93; 1588-1589.
5. Gauguet JM, Von Andrian UH. High endothelial venules. Immunol. Today 1995; 16; 449-457.
6. Girard JP, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol. Today 1995; 16; 449-457.
7. Girard JP, Moussion C, Förster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat. Rev. Immunol. 2012; 12; 762-773.
8. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J. Immunol. 2006; 177; 3369-3379.
9. Hussein MR. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight. Br. J. Dermatol. 2005; 153; 18-21.
10. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77; 1303-1310.
11. Martinet L, Garrido I, Filleron T et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011; 71; 5678-5687.
12. Martinet L, Le Guellec S, Filleron T et al. High endothelial venules (HEVs) in human melanoma lesions. Oncoimmunology 2012; 1; 829-839.
13. Cipponi A, Mercier M, Seremet T et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 2012; 72; 3997-4007.
14. Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 2006; 7; 344-353.
15. Monteagudo C, Ramos D, Pellín-Carcelén A et al. CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. Clin. Exp. Metastasis 2012; 29; 625-637.
16. Monteagudo C, Pellin-Carcelen A, Martin JM, Ramos D. Role of chemokines in melanoma progression. Actas Dermosifiliogr. 2011; 102; 498-504.
17. Baekkevold ES, Yamanaka T, Palframan RT et al. The CCR7 ligand ELC (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J. Exp. Med. 2001; 193; 1105-1112.
18. Carlsen HS, Haraldsen G, Brandtzaeg P, Baekkevold ES. Disparate lymphoid chemokine expression in mice and men: no evidence of CCL21 synthesis by human high endothelial venules. Blood 2005; 106; 444-446.
19. Luther SA, Tang HL, Hyman PL, Farr AG, Cyster JG. Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the elc gene in the plt/plt mouse. Proc. Natl Acad. Sci. USA 2000; 97; 12694-12699.
20. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin. Exp. Metastasis 2008; 25; 345-356.
21. Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur. J. Cancer 2006; 42; 760-767.
22. Frishberg DP, Balch C, Balzer BL et al. Protocol for the examination of specimens from patients with melanoma of the skin. College of American Pathologists, 2012. http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/SkinMelanoma_12protocol.pdf.
23. Rimm DL, Camp RL, Charette LA et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J. 2001; 7; 24-31.
24. Streeter PR, Rouse BT, Butcher EC. Immunohistologic and functional characterization of vascular addressin involved in lymphocyte homing into peripheral lymph nodes. J. Cell Biol. 1988; 107; 1853-1862.
25. Goidin D, Mamessier A, Staquet MJ, Schmitt D, Berthier-Vergnes O. Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and β-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal. Biochem. 2001; 295; 17-21.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 2001; 25; 402-408.
27. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 29; 1960-1964.
28. Dieu-Nosjean MC, Antoine M, Danel C et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 2008; 26; 4410-4417.
29. Hamanishi J, Mandai M, Abiko K et al. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin. Immunol. 2011; 141; 338-347.
30. Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J. Natl Cancer Inst. 1994; 86; 761-769.
31. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363; 711-723.